

Remarks

Applicants have amended the specification to provide the priority claim. Claims 8-10 have been amended to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format. Claims 6-7 have been cancelled without prejudice. New claim 19 has been added. The support for claim 19 can be in the originally filed claim 7. No new matter has been added by these amendments. Claims 1-5 and 8-19 are pending after entry of this amendment.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 101259-1P US.

Respectfully submitted,
/Jianzhong SHEN, Reg.#48076/

Name: Jianzhong Shen
Dated: June 27, 2006
Reg. No.: 48,076
Phone No.: 302-886-8854
Global Intellectual Property, Patents,
AstraZeneca,
1800 Concord Pike,
Wilmington,
DE-19850-5437